Note: Descriptions are shown in the official language in which they were submitted.
CA 02515585 2005-08-22
Specification
Enteric Sustained-Release Fine Particles of Tamsulosin or Its Salt and
Manufacturing Method Thereof
Field of the Invention
The present invention relates to enteric sustained-release fine particles of
tamsulosin or its salt that can be contained in tablets that disintegrate in
the buccal cavity,
and a manufacturing method thereof. In further detail, the present invention
relates to
enteric sustained-release fine particles for tablets that disintegrate in the
buccal cavity,
which comprise (1) tamsulosin or its salt and at least (2) an enterosoluble
substance, and
when necessary contain (3) a water-insoluble substance, and which have the
following
characteristics:
1) A particle diameter of approximately 5 to 250 pm
2) When dissolution tests are performed on tablets that disintegrate in the
buccal
cavity containing these particles by dissolution testing methods cited in the
Japanese Pharmacopoeia,
a) the dissolution rate of tamsulosin or its salt at a pH of 1.2 two hours
after
starting tests is 25°to or less
b) the time when 50% of the tamsulosin or its salt has dissolved at a pH of
6.8
is 0.5 to 5 hours
and a manufacturing method thereof.
Background of the Invention
Tamsulosin and its salts have excellent a~ receptor-blocking activity and are
useful drugs as remedies for the dysuria and the like that accompany
prostatomegaly. It is
reported that when their release is not controlled, these drugs produce
adverse effects in
the form of orthostatic hypotension attributed to a sudden rise in the plasma
concentration. The pharmaceutical preparations containing tamsulosin
hydrochloride that
are being marketed today were developed as enteric capsule pharmaceutical
preparations
comprising enteric sustained-release pauticles of tamsulosin hydrochloride
with which,
based on this knowledge, drug release in the early stages following
administration is
CA 02515585 2005-08-22
adequately controlled and sudden drug release is avoided, with the drug
gradually
released over the 5 to 6 holll'S that follow administration. Fuuthennore, the
enteric
granules contained in this capsule preparation have an average particle
diameter of 350 to
1,000 Vim, and the results of dissolution tests of the capsule preparation
performed by the
inventors in accordance with the methods cited in the Japanese Pharmacopoeia
are as
shown below. The two-hour value is approximately 5% when turned SO rounds by
the
paddle method using 1st fluid (pH 1.2) of the Japanese Phannacopeoia
Dissolution
Testing Method and the 1.5-hour value is approximately 44% when turned 100
rounds by
the paddle method using 2nd fluid (pH of 6.8) of the Japanese Pharmacopoeia.
On the other hand, the importance of improved patient compliance is being
advocated. Various tablets that disintegrate in the buccal cavity quickly are
being
developed so that drugs can be easily taken without water by patients with
weak
swallowing force, including the elderly, children, and the like, and providing
sustained
releasability is also in demand as a result of an increase in the number of
appropriate
drugs.
The following are reports of teclmologies that provide tablets that
disintegrate in
the buccal cavity with sustained releasability: Tablets that disintegrate in
the buccal
cavity are described in US Patent Application No. 6,413,549. These tablets
contain drug
particles and are manufactured by freeze-drying methods. This text discloses
that the
dung release speed becomes faster as the particles become smaller, and that
uniform
coating is possible when the average particle diameter is approximately 500
pm, for
instance, when particle size is 75 to 400 pm, but unifornl coating of
particles of 100 pm
or smaller becomes difficult.
A method of tumbling granulation that can be used for tablets that
disintegrate in
the buccal cavity and a method of manufacturing spherical fine particles with
an average
panicle diameter of 60 to 200 ~m by appropriate coating in order to provide
sustained
releasability and the like are described in International Publication Pamphlet
WO00/24379, and coating with conventional coating bases that are presented in
various
references is disclosed. Moreover, the main objective that particles that have
been
appropriately treated for sustained release can be contained in tablets that
disintegrate in
the buccal cavity is found in both Japanese Kokai Patent No. 11-35451 and W
ternational
2
CA 02515585 2005-08-22
Publication Pamphlet W095/20380.
However, there is no mention of enteric sustained-release fine particles that
can
be used for tablets that disintegrate in the buccal cavity disclosing specific
means
intended for use with tamsulosin or its salts, and using tamsulosin for these
fine particles
is not discussed or disclosed in any reference.
Consequently, there is no knowledge of enteric sustained-release fine
particles
having dissolution profile appropriate for tamsulosin or its salt that are
fine particles with
the average pauticle diameter of approximately 5 to approximately 250 ~m that
can be
used for tablets that disintegrate in the buccal cavity.
Disclosure of the Invention
Under these conditions, the inventors focused on studies of enteric sustained-
release fine particles comprising tamsulosin or its salt that can be used for
tablets that
disintegrate in the buccal cavity. It was possible to reduce the gritty
feeling in the buccal
cavity when tablets that disintegrate in the buccal cavity contain fine
particles with an
average particle diameter of approximately 5 pm to approximately 250 Vim.
However, it
was very difficult to control dissolution of the dmg because the fine
particles had a large
surface area. That is, when dissolution during the early stages of dissolution
tests was
inhibited, eventual dissolution of the drug during the final stages of the
dissolution tests
was also inhibited, but when the intention was to increase dissolution during
the final
stages of the dissolution tests, sufficient inhibition of dissolution during
the early stages
of dissolution tests was not accomplished. Thus, the object of using
tainsulosin or its salt
in enteric sustained-release fine particles with an average particle diameter
of
approximately 5 ~m to approximately 250 ~m that can be used for tablets that
disintegrate in the buccal cavity became clear for the first time, and the
goal became to
control dissolution of fine particles that are smaller than ordinary granule
preparations,
which have an average pauticle diameter of 350 to 1,000 um, and in particular,
to obtain a
dissolution profile that is appropriate for tamsulosin and its salts. v~ light
of the fact that,
taking into consideration the dissolution profile of commercial capsule
preparations, it is
necessary to prevent sudden dissolution in order to control the adverse effect
of
outhostatic hypotension, an object of the present invention is to realize a
50%-dissolution
time of two hours, or to prevent further dissolution, with test fluid at a pH
of 6.8.
3
CA 02515585 2005-08-22
Specifically, an object is to realize a dissolution rate at a pH of 1.2 two
hours after
starting the test of 25% or less and to realize a 50%-dissolution time at a pH
of 6.8 of 0.5
to S hours.
As a result of performing intense studies that would accomplish these
proposes,
the inventors successfully iWibited dissolution during the early stages of
dissolution tests
but avoided excess inhibition of dissolution during the final stages of
dissolution tests of
fine particles comprising tamsulosin or its salt with an average particle
diameter of
approximately 5 pro to approximately 250 pro by selecting the appropriate
mechanism
for controlling drug dissolution.
The present invention was completed as a result of confirming that when these
enteric sustained-release fine particles are contained in tablets that
disintegrate in the
buccal cavity, good disintegration in the buccal cavity, tablet hardness, and
dissolution
and the like are realized.
That is, the present invention relates to
1. enteric sustained-release fine particles for tablets that disintegrate in
the buccal
cavity, which comprise (1) tamsulosin or its salt and at least (2) an
enterosoluble
substance, and when necessary contain (3) a water-insoluble substance, and
which have
the following characteristics:
1) A particle diameter of approximately 5 to 250 pro
2) When dissolution tests are performed on tablets that disintegrate in the
buccal
cavity containing these particles by dissolution testing methods cited in the
Japanese Pharmacopoeia,
a) the dissolution rate of tamsulosin or its salt at a pH of 1.2 two hours
after
starting tests is 25% or less
b) the time when 50% of the tamsulosin or its salt has dissolved at a pH of
6.8
is 0.5 to 5 hours;
2. the enteric sustained-release fine particles for tablets that disintegrate
in the
buccal cavity according to above-mentioned 1, wherein the enterosoluble
substance is an
enterosoluble pol~nner and/or higher fatty acid;
4
CA 02515585 2005-08-22
3. the enteric sustained-release fine particles for tablets that disintegrate
in the
buccal cavity according to above-mentioned 2, wherein the water-insoluble
substance is a
water-insoluble polymer and/or wax;
4. the enteric sustained-release fine particles for tablets that disintegrate
in the
buccal cavity according to above-mentioned 3, characterized in that
dissolution of the
tamsulosin or its salt is controlled by a controlling film and/or matrix;
5. the enteric sustained-release fine particles according to above-mentioned
4,
wherein a layer or matrix containing an enterosoluble base is the layer that
touches the
dissolution fluid or the outermost layer, and the layer containing the water-
insoluble
substance is farther inside the particles than at least the layer of the
enterosoluble base;
and
6. a method of producing enteric sustained-release fine particles for tablets
that
disintegrate in the buccal cavity, which comprise (1) tamsulosin or its salt
and at least (2)
an enterosoluble substance, and when necessary contain (3) a water-insoluble
substance,
and which have the following characteristics:
1) A particle diameter of approximately S to 250 um
2) When dissolution tests are performed on tablets that disintegrate in the
buccal
cavity containing these particles by dissolution testing methods cited in the
Japanese Pharmacopoeia,
a) the dissolution rate of tamsulosin or its salt at a pH of 1.2 two hours
after
starting tests is 25% or less
b) the time when 50% of the tamsulosin or its salt has dissolved at a pH of
6.8
is 0.5 to 5 hours.
The "enterosoluble substance" of the present invention means an enterosoluble
polymer or other enterosoluble base that will at least partially dissolve at a
pH of, for
instance, 5.0 to 9.0, preferably a pH of 5.5 to 7.5. The enterosoluble polymer
is
specifically an enterosoluble cellulose derivative, such as
hydroxypropylmethyl cellulose
acetate succinate, hydroxypropylmethyl cellulose phthalate, hydroxymethylethyl
cellulose phthalate, and carboxymethylethyl cellulose, or an enterosoluble
acrylic
copolymer, such as methacrylic acid-methyl methacrylate copolymer (for
instance, brand
names of Eudragit L100 and Eudragit S, both made by Rolun GmbH), and
methacrylic
CA 02515585 2005-08-22
acid-ethyl acrylate copolymer (for instance, brand names of Eudragit L100-55
and
Eudragit L30-D55, both made by ROlllll GmbH), and higher fatty acids, such as
lauric
acid, myristic acid, palmitic acid, and stearic acid, are given as other
enterosoluble bases.
Of these, methacrylic acid-ethyl acrylate copolymer and stearic acid are
prefen-ed. It is
possible to use a combination of two or more of these enterosoluble
substances.
Furthermore, it is possible not only to realize sustained releasability, but
also to more
easily realize the quality of being enterosoluble, by adding as needed a pH-
independent
water-insoluble substance such as those listed below:
There are no special restrictions to the "water-insoluble substance" of the
present
invention as long as it is a water-insoluble polymer or wax that is
appropriate fox coating
fine particles. Specific water-insoluble polymers are water-insoluble
cellulose ether, such
as ethyl cellulose and Aquacoat (brand name, Asahi Kasei Corp.), water-
insoluble acrylic
acid copolymers, such as ethyl acrylate-methyl methacrylate-
chlorotrimethylammonium
ethyl methacrylate copolymer (for instance, brand name: Eudragit RS, Rohm
GmbH) and
methyl methacrylate-ethyl acrylate copolymer (for instance, brand name:
Eudragit
NE30D, Rohm GmbH), and the like. Water-insoluble cellulose ether, such as
ethyl
cellulose and Aquacoat, is particularly preferred.
Solid fats and oils, such as hydrogenated castor oil, hydrogenated coconut
oil, and
beef tallow, and higher alcohols, such as cetyl alcohol and stearyl alcohol,
are examples
of the waxes of the present invention.
One or a combination of two or more of these polymers and waxes can also be
used for the purpose of controlling dissolution.
In addition, water-soluble polymers, saccharides, salts, and the like can be
mixed
with the above-mentioned water-insoluble polymers or waxes and the like in
order to
facilitate control of drug dissolution from the fine particles that have been
coated by these
substances. Hydroxypropyl cellulose, hydroxypropyhnethyl cellulose, polyvinyl
pyn-olidone, polyvinyl alcohol, and the like are given as these water-soluble
polymers,
maltose, maltitol, and the like are given as these saccharides, and sodium
chloride and the
like are given as these salts. The amount of polymers and saccharides and the
like that is
used here can be adjusted as needed in order to control the dissolution speed
of the drug.
G
CA 02515585 2005-08-22
Moreover, one or a combination of two or more of these polymers and
saccharides and
the like can also be used.
Plasticizes can be added in order to improve film-forming capability.
Tsiacetin,
triethyl citrate, dibutyl sebacate, acetylated monoglyceride, and Eudragit
NE30D (brand
name; ROlnll GmbH) are examples of this plasticizes, and triacetin and
Eudragit NE30D
are prefel-red.
The "enteric sustained-release fine pal-ticles" of the present invention means
sustained-release fine particles that are enterosoluble comprising tamsulosin
or its salt
and an enterosoluble substance, and they can further comprise water-insoluble
substance
as necessary. Moreover, dissolution in the early stages of dissolution tests
was inhibited
and excess inhibition of dissolution during the final stages of dissolution
tests was
avoided with fine particles having an average particle diameter of
approximately S um to
approximately 250 pm comprising tamsulosin or its salt by using the mechanism
for
controlling drug dissolution from enteric sustained-release fine pal-ticles of
the present
invention that is described below:
The following tluree embodiments will be considered as the mechanism for
controlling drug dissolution from enteric sustained-release fine particles of
the present
invention:
a. Film-controlled type
b. Matrix type
c. COIl'1b111at10I1 type of film-controlled type and matrix type
The "film-controlled type" means the type of pharmaceutical preparation with
which drug dissolution is "controlled by a controlling film" and is one where
the dl-ug is
covered by a dissolution-controlling film of a polymer and the like. An
example is a
mechanism for controlling dl-ug dissolution with which polymer and the like is
coated
over a layer comprising the dl-ug and dissolution of the drug is controlled by
the film of
the polymer and the like.
The "matrix type" means the type of pharmaceutical preparation with which drug
dissolution is "controlled by a matrix" and is one where the dl-ug is
dispersed in a base,
such as a polymer or wax. Al example is a mechanism for controlling drug
dissolution
7
CA 02515585 2005-08-22
with which drug dissolution is controlled by holding the drug in the network
structure of
the polymer and the like.
The "combination type" means the type of pharmaceutical preparation with which
dissolution of the drug is "controlled by a controlling film and matrix" and
is one that
uses both the film-controlled type and the matrix type. An example is a
mechanism for
controlling drug dissolution with which dissolution of the drug is controlled
by both
matrix type and film-controlled type thereafter.
Enteric sustained-release fine particles of the film-controlled type can be
obtained
by preparing fine particles with sustained releasability of the film-
controlled type and
then making these fine particles enterosoluble. For instance, sustained-
release fine
particles are obtained by coating a drug on commercial microcrystalline
cellulose grains
(Avicel, Asahi Kasei Corp., brand name: Celphere 102, and the like) as the
core using a
conventional coating device for fluidized bed coating, tumbling fluidized
coating, and the
like, and further coating this with a water-insoluble polymer or wax to form
an film that
controls dissolution. Moreover, it is also possible to obtain sustained-
release fine particles
by preparing a core comprising a drug by high shear granulation, tumbling
fluidized
grmulation, or spray drying and then coating this with a water-insoluble
polymer or wax
to form a film that controls dissolution. Furthermore, enteric sustained-
release fine
particles of the film-controlled type can be obtained by coating an
enterosoluble
substance on the sustained-release fine particles that have been obtained
using the above-
mentioned coating device. Obtaining enteric sustained-release fine particles
of the film-
controlled type is not limited to these methods, but the preferred film-
controlled type
does have a layer comprising water-insoluble substance on the inside and a
layer
comprising enterosoluble substance on the outside.
For instance, as disclosed in Japanese Kokoku Patent No.7-72129, enteric
sustained release particles of the matrix type can be obtained by, for
instance, adding
enterosoluble substance to a drug and microcrystalline cellulose and
performing high
shear granulation or tumbling fluidized granulation. Moreover, these particles
can be
obtained by spray drying, spray cooling, and the like, a solution, suspension,
or melt of a
drug and enterosoluble substance using an appropriate device, such as a spray
dryer.
These particles can also be obtained by coating a solution, suspension, or
melt of a drug
CA 02515585 2005-08-22
and an enterosoluble substance around a core using a conventional coating
device for
fluidized bed coating, tumbling coating, and the like. A water-insoluble
substance can
also be added as needed.
Enteric sustained-release fine particles of the combination type can be
obtained by
preparing sustained-release fine particles comprising a dmg and water-
insoluble
substance and the like by, for instance, high shear granulation, tumbling
fluidized
granulation, spray drying, or spray cooling and then coating this with an
enterosoluble
substance to form a film that controls dissolution. Moreover, it is also
possible to coat a
core with a solution or suspension of a drug and water-insoluble substance to
form
sustained-release fine particles and then coat these with an enterosoluble
substance.
Taking into consideration the size of the sustained-release fine particles
(average
particle diameter of approximately 250 ~m or smaller), in addition to
commercial
microcrystalline cellulose grains, for instance, a conventional crystalline
filler of
approximately 5 um to approximately 150 pm, specifically crystalline lactose,
granular
sugar, sodium chloride, corn starch, and the like, can be used as the core
used by the
above-mentioned method. In this case, a core that has been pre-coated by water-
soluble
polymer, water-insoluble polymer, and the like in order to round the edges of
the filler
that serves as the core can also be used. The solvent that is used to prepare
these
sustained-release fine particles is, for instance, water or an organic
solvent. Examples of
the organic solvent are alcohols, specifically methanol, ethanol, propanol,
isopropanol,
and the like, halogenated alkanes, specifically dichloromethane, chloroform,
chloroethane, trichloroethane, carbon tetrachloride, and the like, ketones,
specifically
acetone, methyl ethyl ketone, and the like, nitriles, specifically
acetonitrile and the like,
and hydrocarbons, specifically n-hexane, cyclohexane, and the like. One of
these organic
solvents or a mixture of two or more at an appropriate ratio can be used, and
a mixture at
an appropriate ratio with water can also be used.
The "tablets that disintegrate in the buccal cavity" of the present invention
means
a pharmaceutical preparation that is tablets or similar to tablets with which
disintegration
in the buccal cavity occurs within a specific amount of time, specifically in
less than 2
minutes, preferably in less than 1 minute. Specific examples are those
disclosed in
International Publication Pamphlet W098/02185, International Publication
Pamphlet
9
CA 02515585 2005-08-22
W095/20380, Japanese Kokai Patent No. 10-182436, Japanese Kokoku Patent No. 5-
500956, Japanese Kokoku Patent No. 62-50445, and Japanese Patent No. 287346.
The enteric sustained-release fine particles of tamsulosin or its salt and
manufacturing method thereof of the present invention will now be described in
detail:
The drug used in the present invention is tamsulosin or its salt and both the
free
form and salts that are phamlaceutically acceptable can be used. Specific
pharmaceutically acceptable salts of tamsulosin are salts of inorganic acids,
such as
hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and
phosphoric acid, and
salts of organic acids, such as formic acid, acetic acid, succinic acid,
oxalic acid, fumaric
acid, malefic acid, lactic acid, malic acid, citric acid, tartaric acid,
glutamic acid, and
aspartic acid. Hydrochlorides are particularly preferred.
The amount of drug that is added is the amount that is effective in terns of
treatment, preferably 0.1 mg to 0.8 mg.
Moreover, other drugs can also be added within a range that does not interfere
with the results of the present invention.
The drug is appropriately treated for sustained release and contained in the
enteric
sustained-release fine particles such that they are fine particles with which
release of the
drug is controlled. There are no special restrictions to the particle diameter
of these
enteric sustained-release fine particles as long as it is within a range with
which the gritty
sensation in the buccal cavity is alleviated. For instance, an average
particle diameter of
approximately 250 p.m or smaller is prefer -ed, an average particle diameter
of
approximately 5 pm to approximately 250 ~m is further preferred, and an
average
particle diameter of approximately 50 ~m to approximately 250 pm is most
preferred. It
is difficult to provide sustained releasability when the average particle
diameter is smaller
than 5 Vim, while there is an awkward feeling, such as a gritty sensation, in
the buccal
cavity when the average pauticle diameter is larger than 250 pm.
Moreover, when dissolution tests are performed by the dissolution testing
methods cited in the Japanese Pharn~acopoeia using tablets that disintegrate
in the buccal
cavity comprising the enteric sustained-release fine pauticles of the present
invention, the
dissolution rate after 2 hours at a pH of 1.2 is 0 to approximately 25%,
preferably 0% to
approximately 15%, in dissolution tests. This is because retention time in the
stomach is
CA 02515585 2005-08-22
said to be 2 hours and therefore, adverse effects can be reduced by holding
dissolution to
approximately 25% or less at the estimated pH inside the stomach.
The mixture ratio of water-insoluble polymer, wax, water-soluble polymer, and
the like used in the present invention is adjusted as needed so that the time
when 50% is
dissolved in dissolution tests at a pH of 6.8 is 30 minutes to 5 hours,
preferably 30
minutes to 4 hours. This is because as with the above-mentioned controlled
dissolution at
a pH of 1.2, it is possible to reduce the adverse effects of tamsulosin by
adjusting 50%
dissolution to these times.
Moreover, the mixture ratio of enterosoluble polymer, plasticizer, and the
like
used in the present invention is adjusted as needed so that the dissolution
rate after two
hours in dissolution tests at a pH of 1.2 is 25% or less.
The above-mentioned embodiments of
a. a film-controlled type,
b. a matrix-type, and
c. a combination of a film-controlled type and a matrix-type
are preferred in order to realize in full the effect of tamsulosin or its salt
as a drug, but
optimization of the dissolution rate as follows is also possible.
~ The layer or matrix containing enterosoluble base is the layer that touches
the
dissolution fluid or at the outermost layer.
~ When the particles contain a water-insoluble substance, the layer containing
the
water-insoluble substance is at least farther inside the particles than the
layer of
enterosoluble base.
The "at least" means that many layers can be present and as long as the layer
containing the water-insoluble substance is farther inside than the layer
containing the
enterosoluble base, other layers can be in between these layers.
The enteric sustained-release fine particles that were obtained can be made,
together with an appropriate filler and binder as necessary, into tablets that
disintegrate in
the buccal cavity. The tablets that disintegrate in the buccal cavity can be
prepared by
conventional methods, and are generally classified as the molded type, wet
method type,
or the ordinary tablet type, and any of these types can be used. Molded
tablets that
disintegrate in the buccal cavity are made by filling and drying a solution or
suspension
11
CA 02515585 2005-08-22
of filler, and the like in a mold, as disclosed in Japanese Kokoku Patent No.
62-50445
and Patent No. 2807346. Molded tablets that disintegrate in the buccal cavity
comprising
enteric sustained-release fine pal-ticles can be made by, for instance,
filling a solution or
suspension of the enteric sustained-release fine pal-ticles of the present
II1Ve11tI0I1, a filler
such as a saccharide, and a binder such as gelatin or agar in a PTP pocket and
then
removing the moisture by a method such as freeze drying, drying under reduced
pressure,
or low-temperature drying. Wet method-type tablets that disintegrate in the
buccal cavity
are made by moistening a filler such as a saccharide, tableting under low
pressure, and
then drying, as disclosed in Japanese Kokai Patent No. 09-309821 and Japanese
Kokai
Patent No. 09-309822. Wet-type tablets that disintegrate in the buccal cavity
comprising
enteric sustained-release fine pal-ticles are prepared by, for instance,
moistening enteric
sustained-release fine particles and a filler such as a saccharide with a
small amount of
water or a mixture of water and alcohol, molding this moistened mixture under
low
pressure, and then drying. Ordinary tablets are prepared by going through
conventional
tableting processes as disclosed in International Publication Pamphlet
W095/20380 and
US Patent Application No. 10/142,081. In order to prepare ordinary tablets
that
disintegrate in the buccal cavity comprising enteric sustained-release fine
particles, for
instance, a saccharide, the enteric sustained-release fine particles of the
present invention,
a filler such as a saccharide of low moldability, and/or a melting saccharide
are
granulated with an aqueous solution of a saccharide of high moldability or a
water-
soluble polymer, tableted, and then submitted to humidification and drying
treatment or
heat treatment. It is possible to make tablets that disintegrate in the buccal
cavity with
improved tablet strength by this treatment. Moreover, as disclosed in Japanese
Kokai
Patent No. 10-182436 and Japanese Kokoku Patent No. 5-500956, tablets that
disintegrate in the buccal cavity can be made by mixing enteric sustained-
release fine
particles, filler such as saccharide, and disintegrating agent or a foamable
component and
then tableting this mixture.
The mixture ratio of enteric sustained-release fine particles in the tablet is
preferably 1 to 50 w/w%, further preferably 5 to 20 w/w%, per tablet weight.
There is a
concern that content uniformity cam~ot be guaranteed if the amount of enteric
sustained-
release fine particles is less than 1 %. Moreover there is a concern that the
propel-ties of
12
CA 02515585 2005-08-22
tablets that disintegrate in the buccal cavity cannot be obtained if the
amount of enteric
sustained-release fine particles is more than 50%.
There are no special restrictions to the "filler" that is used in the present
invention
as long as it is a saccharide or sugar alcohol that is pharmaceutically
acceptable. For
instance, the saccharides of poor moldability in International Publication
Pamphlet
W095/20380, specifically xylitol, erythritol, glucose, mannitol, sucrose, and
lactose, are
prefen-ed, and maimitol, lactose, and erythritol are further prefer-ed.
Moreover, one or a
combination of two or more of these saccharides can be used.
The saccharide of good moldability or water-soluble polymer substance
disclosed
in International Publication Pamphlet W095/20380 is selected as the "binder"
used in the
present invention. Examples of saccharides of good moldability are maltose
(preferably
ame [maltose syrup] powder (maltose content of 83% or higher)), trehalose,
sorbitol, and
maltitol, and maltose and trehalose are prefen-ed. Moreover, examples of water-
soluble
polymer substances are hydroxypropyl cellulose, hydroxypropylmethyl cellulose,
polyvinyl pyn-olidone, polyvinyl alcohol, gum arabic powder, gelatin, and
pullulan. One
or a combination of two or more of these "binders" can be used.
The amount of "filler" used in the present invention is adjusted as needed in
accordance with the amount of enteric sustained-release fine particles added
and/or the
size of the tablet. Normally this amount is preferably 20 to 1,000 mg, further
preferably
50 to S00 mg, still further preferably 100 to 400 mg, per 1 tablet. Moreover,
in terms of
tablet weight it is preferably 30 to 99.5 w/w%, further preferably 50 to 95
w/w%. If the
amount of filler added is less than 20 mg, or less than 30 w/w% in terms of
tablet weight,
there is a possibility that good properties will not be obtained, with a
variety of problems
developing that include delayed disintegration, when this is made into tablets
that
disintegrate in the buccal cavity. There is a concern that it will not be
possible to realize
sufficient disintegration in the buccal cavity. Moreover, if it is more than
1,000 mg, there
may also be too much filler in terms of the amount of saliva in the buccal
cavity and the
tablet will leave uncomfortable feeling in the mouth.
Moreover, normally the amount of "binder" used in the present invention is
preferably 0.5 to 25 w/w%, further preferably 2 to 20 w/w%, still further
preferably 5 to
w/w%, per the weight of the enteric sustained-release fine particles and/or
"filler" that
13
CA 02515585 2005-08-22
is used in the present invention, or 1 to 20 w/w% of the entire
phai~naceutical
preparation. There is a concern that if it is less than 0.5 w/w% per the
weight of the
"filler", or if it is less than 1 w/w% of the entire pharmaceutical
preparation, its function
as a binder will not be realized in full. Moreover, there is a possibility
that if there is more
than 25 w/w% per the weight of the "filler" or more than 20 w/w% of the entire
pharmaceutical preparation, good properties will not be obtained, with a
variety of
problems developing that include delayed disintegration, when it is made into
tablets that
disintegrate in the buccal cavity. The mixture ratio of "binder" to "filler"
used in the
present invention is preferably 99.5:0.5 to 75:25, further preferably 98:2 to
80:20.
A variety of additives that are pharmaceutically acceptable and used as
additives
can be added in addition to the "filler" used in the present invention. These
additives can
also be added together with the filler when the enteric sustained-release fine
particles are
granulated, or they can be mixed with the composition of the present invention
when it is
tableted. Diluent (extender), disintegrating agent, binder, sour flavoring,
foaming agent,
artificial sweetener, fragrance, lubricant, coloring agent, and stabilizer are
given as
examples of these additives. One or a combination of two or more of these
additives can
be used. Moreover, there are no special restrictions to the amount that is
added as long as
it is within a range normally used by experts pharmaceutically and it is an
amount with
which the results of the present invention are not compromised.
Crystalline cellulose and the like can be given as the diluent.
Starches such as corn starch and the like, carmellose calcium, partly
pregelatinized starch, crospovidone, and low-substituted hydroxypropyl
cellulose are
examples of disintegrating agents. Citric acid, tartaric acid, and malic acid
are examples
of sour flavorings. Sodium bicarbonate is an example of a foaming agent.
Saccharine
sodium, dipotassium glycyr-hizinate, aspartame, stevia, and somatin are
examples of
artificial sweeteners. Lemon, lemon-line, orange, and menthol are examples of
flavorings. Calcium stearate, magnesium stearate, sucrose fatty acid ester,
polyethylene
glycol, talc, and stearic acid are examples of lubricants. Food colorings,
such as yellow
food coloring No. 5, red food coloring No. 2, blue food coloring No. 2 and the
like; food
lake coloring; and iron oxide red are examples of coloring agents. The
stabilizer is
14
CA 02515585 2005-08-22
selected for each drug aftex-a-variety of tests have been performed. One or a
combination
of two or more of these additives can be added as needed in appropriate
amounts.
With respect to dissolution when the enteric sustained-release fine particles
of the
present invention are contained in tablets that disintegrate in the buccal
cavity, when
dissolution tests are performed in accordance with the dissolution test method
izz the
Japanese ~hazznacopoeia, the dissolution rate after 2 hours in dissolution
tests at a pfI of
1.2 is 25% or less, preferably 15% or less, and the time when there is 50%
dissolution in
dissolution tests at a pH of 6.8 is 30 minutes to 5 hours, preferably 30
minutes to .4 hours.
This dissolution is dissolution suitable for tamsulosin or its salts in terms
of the advexse
effects of and in terms of the efficacy of tamsulosin or its salt. Dissolution
of the entexic
sustained-release fine particles and dissolution of tablets that disintegrate
izt the buccal
cavity containing enteric sustained-xelease fine particles are approximately
the same, and
dissolution of either can be measured in order to confirm the results of the
enteric
sustained-release fine particles of the present invention.
The process of manufacturing enteric sustained-zelease fine particles of the
present invention, and the process of producing tablets that disintegrate in
the buccal
cavity containing enteric sustained-release fZne particles of the present
invention,
particularly the rn,anufacturing conditions and the like, will now be
described in detail:
The method of manufacturing tablets that disintegrate in the buccal cavity
containing en~tezic sustained-release fine particles of the present invention
is described in
terms of (a) the process of manufacturing enteric sustained-release ~~ne
particles
containing tamsulosin or its salt with which the dissolution speed of the
tamsulosin or its
salt is controlled, and (b) the process of making the "entexxc sustained-
release fine
particles" and "filler," and when necessary, "binder," into tablets that
disintegrate in the
buccal cavity.
Process (a): Process of manufacturing enteric sustained-release ;one particles
The enteric sustained-release fine particles are manufactured using a
conventional
device. There are.no special restrictions to this method and it can be
selected as needed as
long as dissolution is controlled as intended.
Enteric sustainEd-release fz~ae particles of the film~contxolled type are, for
instance, made by coating a core of commercial crystalline cellulose grains or
a
CA 02515585 2005-08-22
conventional crystalline filler having an average particle diameter of
approximately S ~m
to approximately 150 Vim, specifically crystalline lactose, granular sugar,
sodium
chloride, corn starch, and the like, with a drug using a binder, such as
hydroxypropyl
cellulose, and then further coating this product with a polymer substance,
such as water-
insoluble polymer substance or a wax-like substance, to make sustained-release
fine
particles. It is also possible to make sustained-release fine pauticles by
preparing a core
made from a drug, crystalline cellulose, and the like by the high shear
granulation
method, tumbling granulation method, or spray drying method and then coating
this with
a water-insoluble polymer or wax. There are no restrictions to the amount of
water-
insoluble polymer or wax as long as the target dissolution speed can be
realized and it is,
for instance, S to 50%, preferably 10 to 25%, per core containing drug.
Enteric sustained-
release fine particles of the film-controlled type can be obtained by coating
the sustained-
release fine particles that have been obtained with an enterosoluble
substance. There are
no restrictions to the amount of enterosoluble substance as long as the target
dissolution
speed can be realized and it is, for instance, 5 to 100%, preferably 20 to
80%, further
preferably 25 to 50%, per core containing drug.
Enteric sustained-release fine particles of the matrix type are, for instance,
obtained by coating a core of commercial crystalline cellulose grains or a
conventional
crystalline filler, specifically crystalline lactose, granular sugar, sodium
chloride, corn
starch, and the like, with a drug and an enterosoluble substance to make
enteric sustained-
release fine particles. It is also possible to make enteric sustained-release
fine particles by
the high shear granulation method or tumbling agitation method after adding
the
enterosoluble substance to the drug and microcrystalline cellulose. Enteric
sustained-
release fine particles can also be made by spray drying or spray cooling a
solution,
suspension, or melt of the drug and enterosoluble substance using an
appropriate device,
such as spray dryer. There are no restrictions to the amount of substance that
forms the
matrix at this time as long as the target dissolution speed can be
accomplished and it is,
for instance, 10 to 200 parts, preferably SO to 100 parts, per 1 part of drug.
Enteric sustained-release fine particles of the combination type are obtained
by
coating both a core of commercial crystalline cellulose grains or a
conventional
crystalline filler, specifically crystalline lactose, granular sugar, sodium
chloride, corn
1G
CA 02515585 2005-08-22
starch, and the like, with a drug and a polymer substance, such as a water-
insoluble
polymer substance or wax-like substance, to make sustained-release fine
particles. It is
also possible to make sustained-release fine particles by the high shear
granulation
method or tumbling fluidized granulation method after adding water-insoluble
substance
to the drug and microcrystalline cellulose. Sustained release fine particles
can also be
made by spray drying a solution, suspension, or melt of a drug and a water-
insoluble
substance using an appropriate device, such as a spray dryer. An enterosoluble
substance
is further coated on these sustained-release fine particles to make enteric
sustained-
release fine particles of the combination type.
For instance, a fluidized bed granulator is selected for coating. Temperature
is set,
and the spraying liquid volume, drying air volume, and the like are set so
that when
coating is performed using water, temperature is approximately 40°C to
approximately
60°C, and when coating is performed using an organic solvent,
temperature is
approximately 30°C to approximately 60°C. The concentration of
drug that is to be
coated, percentage and amount of polymer substance, and the like can be
adjusted as
needed in accordance with the targeted speed of dissolution.
The enteric sustained-release fine particles are produced by coating sustained-
release fine particles with an enterosoluble polymer by conventional methods.
There are
no special restrictions to this method and it can be selected as needed as
long as
dissolution is controlled as intended. For instance, a fluidized bed
granulator is selected.
Temperature is set, and the spraying liquid volume, drying air volume, and the
like are set
so that when coating is performed using water, temperature is approximately
40°C to
approximately 60°C, and when coating is performed using an organic
solvent,
temperature is approximately 30°C to approximately 60°C. The
concentration of dn~g that
is to be coated, percentage algid amount of polymer substance, and the like,
can be
adjusted as needed in accordance with the targeted speed of dissolution.
Process (b): Process of making tablets that disintegrate in the buccal cavity
The "enteric sustained-release fine particles" and "filler," "binder" when
necessary, are made into tablets that disintegrate in the buccal cavity by
conventional
methods.
17
CA 02515585 2005-08-22
The molded type of tablet that disintegrate in the buccal cavity can be made
by
filling a solution or suspension of enteric sustained-release fine particles,
filler such as
saccharide, and binder such as gelatin or agar in a PTP pocket and then
removing the
water by a method such as freeze drying, drying under reduced pressure, or low-
temperature ventilation drying, as disclosed in Japanese Kokoku Patent No. 62-
50445
and Japanese Patent No. 2807346. The type of tablet that disintegrates in the
buccal
cavity made by the wet method can be obtained by moistening the enteric
sustained-
release fine particles, filler such as saccharide with a small amount of water
or a mixture
of water and alcohol, tableting this moist mixture under low pressure, and
then drying, as
disclosed in Japanese Kokai Patent No. 09-309821 and Japanese Kokai Patent No.
09-
309822. The conventional tableted type of tablet that disintegrates in the
buccal cavity
can be made by granulating enteric sustained-release fine pauticles and filler
such as a
saccharide of poor moldability, and/or molten saccharide with an aqueous
solution of a
saccharide with good moldability or a water-soluble polymer, tableting, and
then
improving tablet strength by humidification and drying treatment or heat
treatment, as
disclosed in International Publication Pamphlet W095/20380 and International
Publication Pamphlet W002/092057. Moreover, the conventional tableted type
that
disintegrates in the buccal cavity can also be made by mixing enteric
sustained-release
fine particles, filler such as saccharide, and disintegrating agent or
foamable component
and then tableting, as disclosed in Japanese Kokai Patent No. 10-182436 and
Japanese
National Publication No. 5-500956.
Consequently, it is possible to make various types of tablets that
disintegrate in
the buccal cavity as long as the enteric sustained-release fine particles of
the present
invention are used.
The "drying" method can be selected from any method commonly used in this
field, including freeze drying, drying under reduced pressure, and drying by
low-
temperature ventilation, as long as it is possible to remove the water.
Fluidized bed granulation, high shear granulation, and tumbling granulation
are
examples of methods that can be selected for "granulation". Of these,
fluidized bed
granulation is preferred in terns of productivity. In this case, it is
preferred that the
saccharide is pulverized with an appropriate pulverizing device, such as a
hammer mill,
18
CA 02515585 2005-08-22
sample mill, or pin mill, if the average particle diameter of the saccharide
that is to be
added is larger than the average particle diameter of the enteric sustained-
release fine
particles.
"Tableting" is performed by conventional methods. This "tableting" can be
performed using, for instance, an ordinary tableting machine, such as a single
tableting
machine or a rotary tableting machine, after adding the necessary additives,
including a
lubricant such as calcium stearate, to the above-mentioned "granulated
product."
Moreover, the above-mentioned " granulated product" can also be made into
tablets using
an external-lubricating tableting machine. Usually, tableting pressure of
approximately
25 to approximately 800 kg/punch is prefers -ed, approximately 50 to
approximately 500
kg/punch is further preferred, approximately 50 to approximately 300 kg/punch
is most
prefer -ed.
Brief Description of the Drawings
Figure 1 is the results of dissolution tests on the tablets and sustained-
release fine
particles in Example 1 using the 1st fluid for the disintegration test of the
Japanese
Pharmacopoeia.
Figure 2 is the results of dissolution tests on the tablets and sustained-
release fine
particles in Example 1 using the 2nd fluid for disintegration tests of the
Japanese
Pharmacopoeia
Description of the Preferred Embodiments
The present invention will now be explained in further detail while referring
to
examples, but the present invention is not limited to these examples.
Methods of Evaluating Tablets that Disintegrate in the Buccal Cavity
[Hardness tests] Determinations were performed using a Schleuniger tablet
hardness meter (Schleuniger Co., Ltd.). The tests are perfornled with 5
tablets and the
mean value is shown. Tablet hardness is represented by the force needed to
break the
tablet (units kp). A larger number indicates a stronger tablet.
[Friability] Determinations were performed using a friability tester (model
PTFR-
A, Phanna Test Co.). Friability is found using 6 or 6.5 g tablets. It is
represented by the
percentage weight loss of a tablet after being tLlI7led 1 OO rounds at a
turning speed of 25
ipm. A smaller value indicates a stronger tablet surface.
19
CA 02515585 2005-08-22
[Disintegration in the buccal cavity tests] Healthy adult males place the
tablet of
the present invention inside their buccal cavity without having any water
inside their
mouth and the time until the tablet is completely disintegl-ated and dissolved
by saliva
only is detel-mined.
[Dissolution tests] These were performed in accordance with Dissolution
Testing
Method 2 in accordance with the 12th Revised Edition of the Japanese
Pharmacopoeia.
Example 1
Eighty gl-ams of tamsulosin hydrochloride and 80 g of hydroxypropyhnethyl
cellulose (TCSE, Shin-Etsu Chemical Co., Ltd.) were dissolved in a mixture of
304 g of
purified water and 2,736 g of methanol. Four-thousand grams of Celphere 102Y
(brand
name, Asahi Kasei Colp.) were introduced to a fluidized bed granulator (Freund
Industries, FLO-S) and coated with this solution by the side spraying method
(spraying
liquid volume of 100 g/min, spraying air pressure of 4 kg/cmz, product
temperature of
40°C, inlet temperature of 80°C) to obtain tamsulosin
hydrochloride particles. Separately,
533 g of ethyl cellulose (Nisshin Chemical Co.) and 187 g of
[hydroxypropylmethyl
cellulose] TCSE (brand name, Shin-Etsu Chemical Co., Ltd.) were dissolved in a
mixture
of 698 g of purified water and 22,582 g of methanol. Four-thousand grams of
tamsulosin
hydrochloride particles were introduced to a fluidized bed granulator (Freund
Industries,
FLO-S) and coated with this solution by the side spraying method (spraying
liquid
volume of 40 g/min, spraying air pressure of 4 kg/cm2, product temperature of
50°C, inlet
temperature of 60°C) to obtain sustained-release fine pal-ticles. Four-
thousand grams of
these sustained-release fine particles were introduced to a fluidized bed
granulator
(Freund Industries, FLO-5) and coated with a mixture of 2,000 g of Aquacoat
(brand
name, Asahi Kasei Corp.), 4,000 g of Eudragit L30D55 (brand name, Rohm GmbH),
667
g of Eudragit NE30D (brand name, Rohm GmbH), and 6,667 g of purified water by
the
side spraying method (spraying liquid VOILlllle Of 4O g/111111, spraying air
pressure of 4
kg/cmz, product temperature of 40°C, inlet temperature of 60°C)
to obtain enteric
sustained-release fine particles. The average pal-ticle diameter of the
enteric sustained-
release fine pal-ticles of the present invention was I 8O plll.
Then 368 g of these enteric sustained-release fine particles, 2,560 g of
mannitol
(Towa Kasei Co., Ltd.), and 640 g of lactose (Domomilk) were gl-anulated
(spraying
CA 02515585 2005-08-22
liquid volume of 200 g/min, spraying air pressure of 1.5 kg/cm2, product
temperature of
29°C, inlet temperature of 80°C, spraying cycle of 10 seconds
spraying-30 seconds
drying) with an aqueous 40 w/w% solution containing 400 g of maltose
(Hayashibara
Co., Ltd., brand name Sumnalt S) in a fluidized bed granulator (Freund
Industries, FLO-
5) to obtain a granulated product.
After further mixing 32 g of calcium stearate with the granulated product that
was
obtained, 200 mg tablets containing 0.2 mg of tamsulosin hydrochloride per
tablet were
made under a tableting pressure of 100 kg/punch and an initial hardness of 1.0
kp using a
rotary tableting machine. Next, these tablets were kept for 18 hours while
heating and
humidifying at 25°C/75% RH using a thermostatic chamber at constant
humidity
(Tabaiespec Co., Ltd., PR-35C). Then they were dried for 3 hours at
30°C and 40% RH.
The tablets that were obtained showed a hardness of 5.9 kp, friability of 0.8%
and
disintegration time in the buccal cavity of 20 seconds.
Experiment 1 (Dissolution test)
Dissolution tests were conducted on the enteric sustained-release fine
particles
and tablets obtained in Example 1. The experimental conditions were 100 rpm by
the
paddle method, and 500 ml each of the 1 st fluid (pH 1.2) and 2nd fluid (pH
6.8) of the
disintegration test method of the Japanese Pharmacopoeia were used as the test
fluids.
As a result of the tests, the dissolution rate of the enteric sustained-
release fine
particles and tablets was 10% and 9%, respectively, 2 hours after starting the
dissolution
test in test fluid at a pH of 1.2. Moreover, the dissolution rate of the
enteric sustained-
release fine particles and tablets in test fluid at a pH of 6.8 was,
respectively, 27% and
25% fifteen minutes after starting the test, 58% and 64% one hour after
starting the test,
and 89% and 93% four hours after starting the test (Figures 1 and 2).
Example 2
Eighty grams of tamsulosin hydrochloride and 80 g of hydroxypropylmethyl
cellulose (TCSE, Shin-Etsu Chemical Co., Ltd.) were dissolved in a mixture of
304 g of
purified water and 2,736 g of methanol. Four-thousand grams of Celphere 102
(brand
name, Asahi Kasei Coip., average particle diameter of approximately 127 pm,
particle
diameter of approximately 50 to approximately 150 yi1) were introduced to a
fluidized
bed granulator (Freund Industries, FLO-S) and coated with this solution by the
side
21
CA 02515585 2005-08-22
spraying method (spraying liquid volume of 100 g/min, spraying air pressure of
4 kg/cm2,
product temperature of 40°C, inlet temperature of 80°C) to
obtain tamsulosin
hydrochloride particles.
Separately, 43.7 g of ethyl cellulose (Nisshin Chemical Co.) and 12.3 g of
hydroxypropylmethyl cellulose (TCSE, brand name, Shin-Etsu Chemical Co., Ltd.)
were
dissolved in a mixture of 43.9 g of purified water and 833.4 g of methanol.
Four-hundred
grams of tamsulosin hydrochloride particles were introduced to a fluidized bed
granulator
(Freund Industries, uni-glatt) and coated with this solution by the side
spraying method
(spraying liquid volume of 6 g/min, spraying air pressure of 4 kg/cm2, product
temperature of 40°C, inlet temperature of 63°C) to obtain
sustained-release fine particles.
' Tlu-ee-hundred grams of these sustained-release fine particles were further
introduced to a fluidized bed granulator (Freund Industries, uni-glatt) and
coated with a
mixture of 90 g of Aquacoat (brand name, Asahi Kasei Corp.), 180 g of Eudragit
L30D55
(brand name, ROlllll GmbH), 30 g of Eudragit NE30D (brand name, Rolun GmbH),
and
300 g of purified water by the side spraying method (spraying liquid volume of
6 g/min,
spraying air pressure of 3 kg/cmZ, product temperature of 40°C, inlet
temperature of
75.5°C) to obtain enteric sustained-release fine particles.
The average particle diameter of the enteric sustained-release fine particles
of the
present invention was 157 ~.m. When drug dissolution at a pH of 1.2 (Japanese
Pharmacopoeia 1 st fluid), it was 4.2% two hours after starting the test. When
drug
dissolution at a pH of 6.8 (Japanese Pharmacopoeia 2nd fluid) was evaluated,
it was
30.0% one hour after starting the test, 50.0% two hours after starting the
test, and 79.4%
six hours after starting the test. Then 92.5 g of these enteric sustained-
release fine
particles, 568.2 g of mannitol (Town Kasei Co., Ltd.) that had been pulverized
with a pin
mill pulverizing device (Hosokawa Micron), 142.1 g of lactose (Domomilk), and
72 g of
erythritol (Nikken Chemicals Co., Ltd.) were granulated (spraying liquid
volume of 15
g/min, spraying air pressure of 0.5 kg/cmz, product temperature of
40°C, inlet
temperature of 70°C, spraying cycle of 15 seconds spraying-30 seconds
drying) with an
aqueous 5 w/w% solution containing 18 g of copolyvidone (BASF, brand name
Kollidon
VA64) in a fluidized bed granulator (Freund Industries, uni-glatt) to obtain a
granulated
product.
22
CA 02515585 2005-08-22
After further mixing 7.2 g of calcium stearate with the granulated product
that
was obtained, 300 mg of tablets containing 0.4 mg of tamsulosin hydrochloride
per tablet
were made under an initial hardness of 0.6 kp using a rotary tableting
machine. Next,
these tablets were heated for 13 minutes at 120°C using a program oven
(Model MOV-
112P, Sanyo) and then set aside to cool for 30 minutes at room temperature to
obtain
tablets that disintegrate in the buccal cavity. The tablets that were obtained
showed a
hardness of 6.8 kp (n = 5), friability of 0.28% (100 rounds) and
disintegration time in the
buccal cavity of 27 seconds (n = 1 ).
When drug dissolution at a pH of 1.2 (Japanese Pharmacopoeia 1 st fluid) was
evaluated, it was 4.9% two hours after starting the test. When drug
dissolution was
evaluated at a pH of 6.8 (Japanese Pharmacopoeia 2nd fluid) was evaluated, it
was 31.1
one hour after starting the test, 52.8% two hours after starting the test, and
88.8% six
hours after starting the test.
Example 3
A mixture of 5.25 g of tamsulosin hydrochloride, 1,102.5 g of Aquacoat (brand
name, Asahi Kasei Corp.), 122.5 g of Eudragit NE30D (brand name, Rolun GmbH),
and
525 g of purified water was prepared. Then 350 g of Celphere 102 (brand name,
Asahi
Kasei Corp., average particle diameter of approximately 127 um, pauticle
diameter of
approximately 50 to approximately 150 Vim) were introduced to a fluidized bed
granulator (Freund Industries, uni-glatt) and coated with this solution by the
side spraying
method (spraying liquid volume of 7 g/min, spraying air pressure of 3.0
kg/cm2, product
temperature of 45°C, inlet temperature of 80°C) to obtain
sustained-release fine particles
that contain tamsulosin hydrochloride.
Then 350 g of these sustained-release fine particles were further introduced
to a
fluidized bed granulator (Freund Industries, uni-glatt) and coated with a
mixture of 117 g
of Aquacoat (brand name, Asahi Kasei Corp.), 408 g of Eudragit L30D55 (brand
name,
Rohm GmbH), 58 g of Eudragit NE30D (brand name, Rohm GmbH), and 583 g of
purified water by the side spraying IllethOd (spraying liquid volume of 6
g/min, spraying
air pressure of 3.5 kg/cm2, product temperature of 43°C, inlet
temperature of 75°C) to
obtain enteric sustained-release fine particles.
23
CA 02515585 2005-08-22
The average pal~licle diameter of the enteric sustained-release fine particles
of the
present invention was 202 pm. Moreover, when dl-ug dissolution was evaluated
at a pH
of 1.2 (Japanese Pharmacopoeia 1 st fluid), it was 13% two hours after
starting the test.
When dI'llg dISSOILIt1011 at a pH of 6.8 (Japanese Pharmacopoeia 2nd fluid)
was evaluated,
it was 39% one hour after stal-ting the test, 55% three hours after stal-ting
the test, and
64% six hours after starting the test.
Then 38 g of these enteric sustained-release fine pal-ticles, 159.6 g of
manrlitol
(Towa Kasei Co., Ltd.), and 159.6 g of lactose (Domomilk), were granulated
(spraying
liquid volume of 15 g/min, spraying air pressure of 1.5 kg/cm2, product
temperature of
35°C, inlet temperature of 90°C, spraying cycle of 60 seconds
spraying-60 seconds
drying) with an aqueous 30 w/w% solution containing 19 g of maltose
(Hayashibara Co.,
Ltd., brand name; Sumnalt S) in a fluidized bed granulator (Freund Industries,
uni-glatt)
to obtain a granulated product.
After further mixing 3.8 g of calcium stearate with the granulated product
that
was obtained, 380 mg of tablets containing 0.2 mg of tamsulosin hydrochloride
per tablet
were made under an initial hardness of 1.3 kp using a rotary tableting
machine. Next,
these tablets were kept for 18 hours while heating and humidifying at
25°C/70% RH
using a thermostatic chamber at constant humidity (Tabaiespec Co., Ltd., built-
in
chamber TBL-2N1AGP). The tablets were then dried for 4 hours at 30°C
and 40% RH to
obtain tablets of the present invention. The tablets that were obtained showed
a hardness
of 4.3 kp, friability of 0.7% and disintegration time in the buccal cavity of
25 seconds.
When drug dissolution at a pH of 1.2 (Japanese Pharmacopoeia 1 st fluid) was
evaluated, it was 1 S% two hours after stal-ting the test. When drug
dissolution at a pH of
6.8 (Japanese Pharmacopoeia 2nd fluid) was evaluated, it was 37% one hour
after starting
the test, 53% tln-ee hours after starting the test, and 63% six hours after
starting the test.
Example 4
After dispersing 1 part tamsulosin hydrochloride in 99 parts molten stearic
acid,
spray congealing (liquid speed of 47 g/minute, atomizer disk turning speed of
2,500 rpm)
was performed using a spray dryer (Ollkawara Kakohki Co., Ltd., DL-8) to
obtain enteric
sustained-release fine particles. The average pal-ticle diameter of the
enteric sustained-
release fine pal-ticles of the present invention was 198 um. Moreover, when dl-
ug
24
CA 02515585 2005-08-22
dissolution was evaluated at a pH of 1.2 (Japanese Pharmacopoeia 1st fluid),
it was 10%
two hours after starting the test. Furthermore, when drug dissolution at a pH
of 6.8
(Japanese Pharmacopoeia 2nd fluid) was evaluated, it was 14.9% one hour after
starting
the test, 46% four hours after starting the test, and 61% six hours after
stauting the test.
A solid pharmaceutical preparation was obtained by drying (25°C, -
760 mmHg)
147 mg of a SLISpeI1s10I1 111ade fr0111 10 parts of these enteric sustained-
release fine
panicles, 0.5 pact agar, 90 parts lactose, 95.5 pants marmitol, 4 parts citric
acid, and 60
pants purified water in the mold. The tablets that were obtained had a
hardness of 2.5 kp
and a disintegration time in the buccal cavity of 6 seconds.
Moreover, when drug dissolution at a pH of 1.2 (Japanese Pharmacopoeia 1st
fluid) of these tablets was evaluated, it was 13.1 % two hours after starting
the test.
Fuuthenmore, when drug dissolution at a pH of 6.8 (Japanese Pharmacopoeia 2nd
fluid)
was evaluated, it was 18% one hour after starting the test, 47% four hours
after starting
the test, and 62% six hours after starting the test.
CA 02515585 2005-08-22
lndustrial Applicability
The present invention presents tablets that disintegrate in the buccal cavity
of
tamsulosin hydrochloride or its salt with which it is possible to inhibit the
adverse effect
of orthostatic hypotension attributed to a sudden rise in plasma
concentrations by making
the tamsulosin hydrochloride or its salt into enteric sustained-release fine
particles.
Moreover, it presents tablets that disintegrate in the buccal cavity of
tamsulosin
hydrochloride or its salt that have been given what at a glance are opposing
qualities in
that although their property of being tablets that are disintegrated in the
buccal cavity is
not compromised and they are quickly disintegrated and dissolved in the buccal
cavity,
they have sustained releasability as a result of being made into enteric
sustained-release
fine particles the size of which does not produce a gritty sensation in the
buccal cavity.
26
